Daniel Fulton currently serves as the Director of Integrated Delivery Networks (IDNs) at Madrigal Pharmaceuticals, where he leverages his extensive background in pharmaceutical sales and managed care to drive innovative strategies that enhance patient outcomes in the realm of Nonalcoholic Steatohepatitis (NASH). In this pivotal...
Daniel Fulton currently serves as the Director of Integrated Delivery Networks (IDNs) at Madrigal Pharmaceuticals, where he leverages his extensive background in pharmaceutical sales and managed care to drive innovative strategies that enhance patient outcomes in the realm of Nonalcoholic Steatohepatitis (NASH). In this pivotal role, Daniel is dedicated to forging strategic partnerships with the largest health systems across the United States, focusing on improving the quality of care for patients suffering from this complex liver disease. His passion for building and launching successful sales teams is evident in his ability to cultivate a high-performance culture that consistently meets and exceeds corporate sales objectives.
Daniel’s diverse background, which spans competitive athletics, finance, and sales leadership, equips him with a unique skill set that is particularly effective in the Specialty and Rare Disease sectors. His expertise in hospital sales and product launch strategies has been instrumental in navigating the complexities of the pharmaceutical industry, particularly in areas such as oncology, cardiology, and gastroenterology. By utilizing his deep understanding of reimbursement processes and sales operations, Daniel ensures that his teams are not only effective in their outreach but also adept at addressing the intricate needs of managed care organizations.
Key projects under Daniel's leadership include the development of targeted educational initiatives for healthcare providers, aimed at increasing awareness and understanding of NASH, as well as the implementation of data-driven sales strategies that optimize resource allocation and enhance sales effectiveness. His commitment to improving patient care through collaboration and innovation positions him as a leader in the pharmaceutical landscape, making significant strides in the fight against NASH and its associated challenges.
